Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT04514419
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04361812
- Locations
- 🇨🇳
Anhui Peng, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath